Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. I: Structuring centers for the multidisciplinary clinical administration and management of CAR-T cell therapy patients

Chimeric antigen receptor T-cells (CAR-T cells) are a new modality of oncological treatment which has demonstrated impressive response in refractory or relapsed diseases, such as acute lymphoblastic leukemia (ALL), lymphomas, and myeloma but is also associated with unique and potentially life-threat...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Diego V. Clé, Alexandre V. Hirayama, Alvaro J. Alencar, Luciano J. Costa, João V.P. Feliciano, Ederson R. Mattos, Ana C. Cordeiro, Marco Aurélio Salvino, George M. Navarro Barros, Marcos de Lima, Phillip Scheinberg, Renato L. Guerino-Cunha
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	Cellular therapy CAR-T cells Complication management Cytokine release syndrome Neurotoxicity Center structuring Diseases of the blood and blood-forming organs RC633-647.5
Acceso en línea:	https://doaj.org/article/32bfb39222994220bef5615e14a74f60
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:32bfb39222994220bef5615e14a74f60
record_format	dspace
spelling	oai:doaj.org-article:32bfb39222994220bef5615e14a74f602021-11-18T04:50:56ZAssociação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. I: Structuring centers for the multidisciplinary clinical administration and management of CAR-T cell therapy patients2531-137910.1016/j.htct.2021.09.001https://doaj.org/article/32bfb39222994220bef5615e14a74f602021-11-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2531137921001358https://doaj.org/toc/2531-1379Chimeric antigen receptor T-cells (CAR-T cells) are a new modality of oncological treatment which has demonstrated impressive response in refractory or relapsed diseases, such as acute lymphoblastic leukemia (ALL), lymphomas, and myeloma but is also associated with unique and potentially life-threatening toxicities. The most common adverse events (AEs) include cytokine release syndrome (CRS), neurological toxicities, such as the immune effector cell-associated neurotoxicity syndrome (ICANS), cytopenias, infections, and hypogammaglobulinemia. These may be severe and require admission of the patient to an intensive care unit. However, these AEs are manageable when recognized early and treated by a duly trained team. The objective of this article is to report a consensus compiled by specialists in the fields of oncohematology, bone marrow transplantation, and cellular therapy describing recommendations on the Clinical Centers preparation, training of teams that will use CAR-T cells, and leading clinical questions as to their use and the management of potential complications.Diego V. CléAlexandre V. HirayamaAlvaro J. AlencarLuciano J. CostaJoão V.P. FelicianoEderson R. MattosAna C. CordeiroMarco Aurélio SalvinoGeorge M. Navarro BarrosMarcos de LimaPhillip ScheinbergRenato L. Guerino-CunhaElsevierarticleCellular therapyCAR-T cellsComplication managementCytokine release syndromeNeurotoxicityCenter structuringDiseases of the blood and blood-forming organsRC633-647.5ENHematology, Transfusion and Cell Therapy, Vol 43, Iss , Pp S3-S12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Cellular therapy CAR-T cells Complication management Cytokine release syndrome Neurotoxicity Center structuring Diseases of the blood and blood-forming organs RC633-647.5
spellingShingle	Cellular therapy CAR-T cells Complication management Cytokine release syndrome Neurotoxicity Center structuring Diseases of the blood and blood-forming organs RC633-647.5 Diego V. Clé Alexandre V. Hirayama Alvaro J. Alencar Luciano J. Costa João V.P. Feliciano Ederson R. Mattos Ana C. Cordeiro Marco Aurélio Salvino George M. Navarro Barros Marcos de Lima Phillip Scheinberg Renato L. Guerino-Cunha Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. I: Structuring centers for the multidisciplinary clinical administration and management of CAR-T cell therapy patients
description	Chimeric antigen receptor T-cells (CAR-T cells) are a new modality of oncological treatment which has demonstrated impressive response in refractory or relapsed diseases, such as acute lymphoblastic leukemia (ALL), lymphomas, and myeloma but is also associated with unique and potentially life-threatening toxicities. The most common adverse events (AEs) include cytokine release syndrome (CRS), neurological toxicities, such as the immune effector cell-associated neurotoxicity syndrome (ICANS), cytopenias, infections, and hypogammaglobulinemia. These may be severe and require admission of the patient to an intensive care unit. However, these AEs are manageable when recognized early and treated by a duly trained team. The objective of this article is to report a consensus compiled by specialists in the fields of oncohematology, bone marrow transplantation, and cellular therapy describing recommendations on the Clinical Centers preparation, training of teams that will use CAR-T cells, and leading clinical questions as to their use and the management of potential complications.
format	article
author	Diego V. Clé Alexandre V. Hirayama Alvaro J. Alencar Luciano J. Costa João V.P. Feliciano Ederson R. Mattos Ana C. Cordeiro Marco Aurélio Salvino George M. Navarro Barros Marcos de Lima Phillip Scheinberg Renato L. Guerino-Cunha
author_facet	Diego V. Clé Alexandre V. Hirayama Alvaro J. Alencar Luciano J. Costa João V.P. Feliciano Ederson R. Mattos Ana C. Cordeiro Marco Aurélio Salvino George M. Navarro Barros Marcos de Lima Phillip Scheinberg Renato L. Guerino-Cunha
author_sort	Diego V. Clé
title	Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. I: Structuring centers for the multidisciplinary clinical administration and management of CAR-T cell therapy patients
title_short	Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. I: Structuring centers for the multidisciplinary clinical administration and management of CAR-T cell therapy patients
title_full	Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. I: Structuring centers for the multidisciplinary clinical administration and management of CAR-T cell therapy patients
title_fullStr	Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. I: Structuring centers for the multidisciplinary clinical administration and management of CAR-T cell therapy patients
title_full_unstemmed	Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. I: Structuring centers for the multidisciplinary clinical administration and management of CAR-T cell therapy patients
title_sort	associação brasileira de hematologia, hemoterapia e terapia celular consensus on genetically modified cells. i: structuring centers for the multidisciplinary clinical administration and management of car-t cell therapy patients
publisher	Elsevier
publishDate	2021
url	https://doaj.org/article/32bfb39222994220bef5615e14a74f60
work_keys_str_mv	AT diegovcle associacaobrasileiradehematologiahemoterapiaeterapiacelularconsensusongeneticallymodifiedcellsistructuringcentersforthemultidisciplinaryclinicaladministrationandmanagementofcartcelltherapypatients AT alexandrevhirayama associacaobrasileiradehematologiahemoterapiaeterapiacelularconsensusongeneticallymodifiedcellsistructuringcentersforthemultidisciplinaryclinicaladministrationandmanagementofcartcelltherapypatients AT alvarojalencar associacaobrasileiradehematologiahemoterapiaeterapiacelularconsensusongeneticallymodifiedcellsistructuringcentersforthemultidisciplinaryclinicaladministrationandmanagementofcartcelltherapypatients AT lucianojcosta associacaobrasileiradehematologiahemoterapiaeterapiacelularconsensusongeneticallymodifiedcellsistructuringcentersforthemultidisciplinaryclinicaladministrationandmanagementofcartcelltherapypatients AT joaovpfeliciano associacaobrasileiradehematologiahemoterapiaeterapiacelularconsensusongeneticallymodifiedcellsistructuringcentersforthemultidisciplinaryclinicaladministrationandmanagementofcartcelltherapypatients AT edersonrmattos associacaobrasileiradehematologiahemoterapiaeterapiacelularconsensusongeneticallymodifiedcellsistructuringcentersforthemultidisciplinaryclinicaladministrationandmanagementofcartcelltherapypatients AT anaccordeiro associacaobrasileiradehematologiahemoterapiaeterapiacelularconsensusongeneticallymodifiedcellsistructuringcentersforthemultidisciplinaryclinicaladministrationandmanagementofcartcelltherapypatients AT marcoaureliosalvino associacaobrasileiradehematologiahemoterapiaeterapiacelularconsensusongeneticallymodifiedcellsistructuringcentersforthemultidisciplinaryclinicaladministrationandmanagementofcartcelltherapypatients AT georgemnavarrobarros associacaobrasileiradehematologiahemoterapiaeterapiacelularconsensusongeneticallymodifiedcellsistructuringcentersforthemultidisciplinaryclinicaladministrationandmanagementofcartcelltherapypatients AT marcosdelima associacaobrasileiradehematologiahemoterapiaeterapiacelularconsensusongeneticallymodifiedcellsistructuringcentersforthemultidisciplinaryclinicaladministrationandmanagementofcartcelltherapypatients AT phillipscheinberg associacaobrasileiradehematologiahemoterapiaeterapiacelularconsensusongeneticallymodifiedcellsistructuringcentersforthemultidisciplinaryclinicaladministrationandmanagementofcartcelltherapypatients AT renatolguerinocunha associacaobrasileiradehematologiahemoterapiaeterapiacelularconsensusongeneticallymodifiedcellsistructuringcentersforthemultidisciplinaryclinicaladministrationandmanagementofcartcelltherapypatients
_version_	1718424966233325568

Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. I: Structuring centers for the multidisciplinary clinical administration and management of CAR-T cell therapy patients

Ejemplares similares